vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and Applied Digital Corp. (APLD). Click either name above to swap in a different company.
Applied Digital Corp. is the larger business by last-quarter revenue ($126.6M vs $71.7M, roughly 1.8× Adaptive Biotechnologies Corp). Applied Digital Corp. runs the higher net margin — -11.4% vs -18.9%, a 7.5% gap on every dollar of revenue. On growth, Applied Digital Corp. posted the faster year-over-year revenue change (98.2% vs 51.0%). Adaptive Biotechnologies Corp produced more free cash flow last quarter ($1.4M vs $-567.9M). Over the past eight quarters, Applied Digital Corp.'s revenue compounded faster (70.9% CAGR vs 30.8%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
BAE Systems Digital Intelligence is an international defence and security technology firm owned by BAE Systems. They specialize in delivering digital solutions that enable rapid, data-driven decision-making. Their services, solutions and products span customers in Law Enforcement, National Security, Government Departments and Government Enterprises, Critical National Infrastructure, Telecommunications, the Military, and Space.
ADPT vs APLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $126.6M |
| Net Profit | $-13.6M | $-14.4M |
| Gross Margin | 74.6% | 20.6% |
| Operating Margin | -17.8% | -24.5% |
| Net Margin | -18.9% | -11.4% |
| Revenue YoY | 51.0% | 98.2% |
| Net Profit YoY | 59.7% | 89.6% |
| EPS (diluted) | $-0.08 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $126.6M | ||
| Q3 25 | $94.0M | $64.2M | ||
| Q2 25 | $58.9M | $-33.3M | ||
| Q1 25 | $52.4M | $52.9M | ||
| Q4 24 | $47.5M | $63.9M | ||
| Q3 24 | $46.4M | $60.7M | ||
| Q2 24 | $43.2M | $43.7M | ||
| Q1 24 | $41.9M | $43.3M |
| Q4 25 | $-13.6M | $-14.4M | ||
| Q3 25 | $9.5M | $-16.9M | ||
| Q2 25 | $-25.6M | $-52.5M | ||
| Q1 25 | $-29.9M | $-35.6M | ||
| Q4 24 | $-33.7M | $-138.7M | ||
| Q3 24 | $-32.1M | $-4.2M | ||
| Q2 24 | $-46.2M | $-64.5M | ||
| Q1 24 | $-47.5M | $-62.8M |
| Q4 25 | 74.6% | 20.6% | ||
| Q3 25 | 80.7% | 13.4% | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | 7.1% | ||
| Q4 24 | 62.0% | 18.0% | ||
| Q3 24 | 64.1% | -0.6% | ||
| Q2 24 | 55.3% | -9.1% | ||
| Q1 24 | 56.9% | -8.6% |
| Q4 25 | -17.8% | -24.5% | ||
| Q3 25 | 10.9% | -34.7% | ||
| Q2 25 | -42.5% | — | ||
| Q1 25 | -56.4% | -35.8% | ||
| Q4 24 | -71.3% | -29.1% | ||
| Q3 24 | -70.3% | 15.6% | ||
| Q2 24 | -109.6% | -68.4% | ||
| Q1 24 | -116.5% | -128.8% |
| Q4 25 | -18.9% | -11.4% | ||
| Q3 25 | 10.2% | -26.4% | ||
| Q2 25 | -43.5% | 157.8% | ||
| Q1 25 | -56.9% | -67.2% | ||
| Q4 24 | -71.0% | -217.2% | ||
| Q3 24 | -69.1% | -7.0% | ||
| Q2 24 | -107.0% | -147.5% | ||
| Q1 24 | -113.5% | -145.0% |
| Q4 25 | $-0.08 | $-0.07 | ||
| Q3 25 | $0.06 | $-0.07 | ||
| Q2 25 | $-0.17 | $-0.31 | ||
| Q1 25 | $-0.20 | $-0.16 | ||
| Q4 24 | $-0.22 | $-0.66 | ||
| Q3 24 | $-0.22 | $-0.03 | ||
| Q2 24 | $-0.31 | $-0.57 | ||
| Q1 24 | $-0.33 | $-0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $218.8M | $1.4B |
| Total Assets | $512.7M | $5.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $1.9B | ||
| Q3 25 | $55.0M | $73.9M | ||
| Q2 25 | $43.2M | $41.6M | ||
| Q1 25 | $50.6M | $68.7M | ||
| Q4 24 | $47.9M | $286.2M | ||
| Q3 24 | $38.1M | $58.2M | ||
| Q2 24 | $59.8M | $3.3M | ||
| Q1 24 | $71.2M | $4.4M |
| Q4 25 | $218.8M | $1.4B | ||
| Q3 25 | $204.4M | $1.0B | ||
| Q2 25 | $179.7M | $497.7M | ||
| Q1 25 | $190.4M | $454.6M | ||
| Q4 24 | $202.7M | $434.6M | ||
| Q3 24 | $223.8M | $241.8M | ||
| Q2 24 | $241.6M | $124.8M | ||
| Q1 24 | $274.9M | $118.5M |
| Q4 25 | $512.7M | $5.2B | ||
| Q3 25 | $490.6M | $2.4B | ||
| Q2 25 | $496.6M | $1.9B | ||
| Q1 25 | $510.9M | $1.7B | ||
| Q4 24 | $539.4M | $1.5B | ||
| Q3 24 | $558.5M | $937.7M | ||
| Q2 24 | $584.9M | $762.9M | ||
| Q1 24 | $620.3M | $643.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $-15.8M |
| Free Cash FlowOCF − Capex | $1.4M | $-567.9M |
| FCF MarginFCF / Revenue | 2.0% | -448.6% |
| Capex IntensityCapex / Revenue | 0.9% | 436.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $-1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $-15.8M | ||
| Q3 25 | $-7.1M | $-82.0M | ||
| Q2 25 | $-12.4M | $6.9M | ||
| Q1 25 | $-28.5M | $5.9M | ||
| Q4 24 | $-12.5M | $-52.3M | ||
| Q3 24 | $-27.1M | $-75.9M | ||
| Q2 24 | $-17.3M | $-34.1M | ||
| Q1 24 | $-38.4M | $38.8M |
| Q4 25 | $1.4M | $-567.9M | ||
| Q3 25 | $-7.5M | $-331.4M | ||
| Q2 25 | $-13.1M | $-191.4M | ||
| Q1 25 | $-29.7M | $-251.6M | ||
| Q4 24 | $-12.6M | $-223.3M | ||
| Q3 24 | $-27.4M | $-130.7M | ||
| Q2 24 | $-19.0M | $-88.9M | ||
| Q1 24 | $-39.9M | $-2.3M |
| Q4 25 | 2.0% | -448.6% | ||
| Q3 25 | -8.0% | -516.1% | ||
| Q2 25 | -22.2% | 574.8% | ||
| Q1 25 | -56.7% | -475.4% | ||
| Q4 24 | -26.5% | -349.6% | ||
| Q3 24 | -59.0% | -215.3% | ||
| Q2 24 | -44.1% | -203.5% | ||
| Q1 24 | -95.2% | -5.4% |
| Q4 25 | 0.9% | 436.1% | ||
| Q3 25 | 0.4% | 388.4% | ||
| Q2 25 | 1.1% | -595.4% | ||
| Q1 25 | 2.4% | 486.6% | ||
| Q4 24 | 0.2% | 267.8% | ||
| Q3 24 | 0.7% | 90.3% | ||
| Q2 24 | 4.0% | 125.4% | ||
| Q1 24 | 3.6% | 95.0% |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
APLD
| HPC Hosting Business | $85.0M | 67% |
| Data Center Hosting Business | $41.6M | 33% |
